Dr Hafiz Abdul-Aziz is a Clinical Research Pharmacist at The University of Queensland, Frazer Institute and an NHMRC Emerging Leadership Fellow (EL2, 2026). He leads the Clinical Dosing Studies and Knowledge Translation Workstream within the Antimicrobial Optimisation Group and the Centre for Research Excellence for Personalising Antimicrobial Dosing to Reduce Resistance (CRE RESPOND).
After completing a Bachelor of Pharmacy at the International Islamic University Malaysia (IIUM) and a Master of Clinical Pharmacy at Universiti Kebangsaan Malaysia (UKM), Hafiz moved to Australia to undertake his PhD at The University of Queensland. He completed his doctorate in 2016 under the mentorship of Professor Jason Roberts, Associate Professor Christine Staatz and Professor Jeffrey Lipman, focusing on pharmacokinetic and pharmacodynamic (PK/PD) optimisation of beta-lactam antibiotics in critically ill patients.
Driven by a passion for improving outcomes for patients with severe infections, Hafiz's research focuses on developing innovative approaches to optimise antimicrobial dosing and delivery in the intensive care unit. His areas of expertise include antimicrobial PK/PD, therapeutic drug monitoring, prolonged beta-lactam infusions, model-informed precision dosing, extracorporeal membrane oxygenation (ECMO), renal replacement therapy (RRT), and multicentre population pharmacokinetic studies.
A strong advocate for collaborative research, Hafiz has built an international network spanning more than 100 researchers across 36 countries. Over the past five years, he has led or coordinated eight multinational antimicrobial pharmacokinetic studies, including ASAP ECMO, BLING III, BLING III PK/PD and PNEUDOS. Collectively, these projects have helped advance knowledge around optimal antimicrobial therapy for critically ill patients worldwide.
Hafiz has authored more than 100 peer-reviewed publications and book chapters, with his work cited more than 5,000 times. He is a Fellow of the International Society of Antimicrobial Chemotherapy (ISAC) and currently serves as Chair of the ISAC Infections in the ICU and Sepsis Working Group. He is also an active member of ECMOPharmNet, an international multidisciplinary network dedicated to advancing ECMO pharmacology research.
When reflecting on his career, Hafiz credits much of his success to the mentors, colleagues and collaborators who have supported him along the way. He remains particularly grateful for the opportunity to work alongside leaders in antimicrobial dosing research, whose guidance helped shape both his scientific thinking and collaborative approach to research.
Outside of work, Hafiz enjoys running, following sport and proudly embracing his status as a dedicated Swiftie.
